Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Development and impact of prescription opioid abuse deterrent formulation technologies.

Alexander L, Mannion RO, Weingarten B, Fanelli RJ, Stiles GL.

Drug Alcohol Depend. 2014 May 1;138:1-6. doi: 10.1016/j.drugalcdep.2014.02.006. Epub 2014 Feb 16. Review.

PMID:
24613631
2.

Selective publication of antidepressant trials.

Ninan PT, Poole RM, Stiles GL.

N Engl J Med. 2008 May 15;358(20):2181; author reply 2181-2. No abstract available.

PMID:
18494076
3.

Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke.

Feuerstein GZ, Zaleska MM, Krams M, Wang X, Day M, Rutkowski JL, Finklestein SP, Pangalos MN, Poole M, Stiles GL, Ruffolo RR, Walsh FL.

J Cereb Blood Flow Metab. 2008 Jan;28(1):217-9. Epub 2007 Jun 20. Review.

PMID:
17579658
4.

Should an academic radiation oncologist be allowed to "opt out" of medicare?

Halperin EC, Fulkerson WJ, Kaufman R, Newman P, Stiles GL.

J Am Coll Radiol. 2005 Oct;2(10):841-5. Review.

PMID:
17411944
5.

Wyeth Pharmaceutical's perspective on vaccine production.

Stiles GL.

Md Med. 2005 Winter;6(1):22-3. No abstract available.

PMID:
15869103
6.

Outcomes following elective percutaneous coronary intervention without on-site surgical backup in a community hospital.

Paraschos A, Callwood D, Wightman MB, Tcheng JE, Phillips HR, Stiles GL, Daniel JM, Sketch MH Jr.

Am J Cardiol. 2005 May 1;95(9):1091-3.

PMID:
15842979
7.

The role of receptor structure in determining adenosine receptor activity.

Olah ME, Stiles GL.

Pharmacol Ther. 2000 Feb;85(2):55-75. Review.

PMID:
10722120
10.
11.

To train or not to train.

Tilley AH, Stiles GL.

Am Heart J. 1999 Sep;138(3 Pt 1):390-1. No abstract available.

PMID:
10467183
13.

Oxidative stress increases A1 adenosine receptor expression by activating nuclear factor kappa B.

Nie Z, Mei Y, Ford M, Rybak L, Marcuzzi A, Ren H, Stiles GL, Ramkumar V.

Mol Pharmacol. 1998 Apr;53(4):663-9.

PMID:
9547356
14.

Adenosine A1 receptor and bipolar affective disorder: systematic screening of the gene and association studies.

Deckert J, Nöthen MM, Albus M, Franzek E, Rietschel M, Ren H, Stiles GL, Knapp M, Weigelt B, Maier W, Beckmann H, Propping P.

Am J Med Genet. 1998 Feb 7;81(1):18-23.

PMID:
9514582
15.

A single-stranded DNA binding site in the human A1 adenosine receptor gene promoter.

Ren H, Stiles GL.

Mol Pharmacol. 1998 Jan;53(1):43-51.

PMID:
9443931
16.

Pharmacological characterization of novel A3 adenosine receptor-selective antagonists.

Jacobson KA, Park KS, Jiang JL, Kim YC, Olah ME, Stiles GL, Ji XD.

Neuropharmacology. 1997 Sep;36(9):1157-65.

17.

Structure-function analysis of inhibitory adenosine receptor regulation.

Palmer TM, Stiles GL.

Neuropharmacology. 1997 Sep;36(9):1141-7. Review.

PMID:
9364469
18.

Induction of multiple effects on adenylyl cyclase regulation by chronic activation of the human A3 adenosine receptor.

Palmer TM, Harris CA, Coote J, Stiles GL.

Mol Pharmacol. 1997 Oct;52(4):632-40.

PMID:
9380026
19.
20.

Site-directed mutagenesis and chimeric receptors in the study of receptor-ligand binding.

Olah ME, Stiles GL.

Methods Mol Biol. 1997;83:25-43. Review. No abstract available.

PMID:
9210134
21.

Multifunctional G proteins. Searching for functions in the heart.

Stiles GL.

Circulation. 1996 Aug 15;94(4):602-3. No abstract available.

PMID:
8772675
22.

Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.

van Rhee AM, Jiang JL, Melman N, Olah ME, Stiles GL, Jacobson KA.

J Med Chem. 1996 Jul 19;39(15):2980-9.

PMID:
8709132
23.
24.

Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists.

Karton Y, Jiang JL, Ji XD, Melman N, Olah ME, Stiles GL, Jacobson KA.

J Med Chem. 1996 Jun 7;39(12):2293-301.

PMID:
8691424
25.

A SURVEY OF NONXANTHINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS.

Siddiqi SM, Ji XD, Melman N, Olah ME, Jain R, Evans P, Glashofer M, Padgett WL, Cohen LA, Daly JW, Stiles GL, Jacobson KA.

Nucleosides Nucleotides. 1996;15(1-3):693-717.

29.

'A riddle wrapped in a mystery inside an enigma'.

Stiles GL.

Circulation. 1995 Oct 1;92(7):1678-9. No abstract available.

PMID:
7671348
30.

Human adenosine A1 receptor gene: systematic screening for DNA sequence variation and linkage mapping on chromosome 1q31-32.1 using a silent polymorphism in the coding region.

Deckert J, Nöthen MM, Bryant SP, Ren H, Wolf HK, Stiles GL, Spurr NK, Propping P.

Biochem Biophys Res Commun. 1995 Sep 14;214(2):614-21.

PMID:
7677773
31.

Differential interaction with and regulation of multiple G-proteins by the rat A3 adenosine receptor.

Palmer TM, Gettys TW, Stiles GL.

J Biol Chem. 1995 Jul 14;270(28):16895-902.

32.

A3-adenosine receptors: design of selective ligands and therapeutic prospects.

Jacobson KA, Kim HO, Siddiqi SM, Olah ME, Stiles GL, von Lubitz DK.

Drugs Future. 1995 Jul;20(7):689-699. No abstract available.

33.

Adenosine receptors.

Palmer TM, Stiles GL.

Neuropharmacology. 1995 Jul;34(7):683-94. Review. No abstract available.

PMID:
8532135
34.

Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.

Jacobson KA, Siddiqi SM, Olah ME, Ji XD, Melman N, Bellamkonda K, Meshulam Y, Stiles GL, Kim HO.

J Med Chem. 1995 May 12;38(10):1720-35.

35.

Adenosine receptors: protein and gene structure.

Olah ME, Ren H, Stiles GL.

Arch Int Pharmacodyn Ther. 1995 Jan-Feb;329(1):135-50. Review.

PMID:
7639615
36.

Adenosine receptor subtypes: characterization and therapeutic regulation.

Olah ME, Stiles GL.

Annu Rev Pharmacol Toxicol. 1995;35:581-606. Review.

PMID:
7598508
37.

Selective ligands for rat A3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives.

Kim HO, Ji XD, Melman N, Olah ME, Stiles GL, Jacobson KA.

J Med Chem. 1994 Nov 11;37(23):4020-30.

38.

2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.

Kim HO, Ji XD, Siddiqi SM, Olah ME, Stiles GL, Jacobson KA.

J Med Chem. 1994 Oct 14;37(21):3614-21.

40.

Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.

Kim HO, Ji XD, Melman N, Olah ME, Stiles GL, Jacobson KA.

J Med Chem. 1994 Sep 30;37(20):3373-82.

41.
42.

A binding site model and structure-activity relationships for the rat A3 adenosine receptor.

van Galen PJ, van Bergen AH, Gallo-Rodriguez C, Melman N, Olah ME, IJzerman AP, Stiles GL, Jacobson KA.

Mol Pharmacol. 1994 Jun;45(6):1101-11.

43.

Desensitization of the canine A2a adenosine receptor: delineation of multiple processes.

Palmer TM, Gettys TW, Jacobson KA, Stiles GL.

Mol Pharmacol. 1994 Jun;45(6):1082-94.

44.
45.

125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor.

Olah ME, Gallo-Rodriguez C, Jacobson KA, Stiles GL.

Mol Pharmacol. 1994 May;45(5):978-82.

46.
47.

The new biology of adenosine receptors.

Palmer TM, Stiles GL.

Adv Enzymol Relat Areas Mol Biol. 1994;69:83-120. Review. No abstract available.

PMID:
7817871
48.

A role for central A3-adenosine receptors. Mediation of behavioral depressant effects.

Jacobson KA, Nikodijević O, Shi D, Gallo-Rodriguez C, Olah ME, Stiles GL, Daly JW.

FEBS Lett. 1993 Dec 20;336(1):57-60.

49.

Functional consequences of A1 adenosine-receptor phosphorylation by the beta-adrenergic receptor kinase.

Ramkumar V, Kwatra M, Benovic JL, Stiles GL, Stilesa GL.

Biochim Biophys Acta. 1993 Oct 7;1179(1):89-97. Erratum in: Biochim Biophys Acta 1994 Jan 13;1220(2):229.

PMID:
8399355
50.

Supplemental Content

Loading ...
Support Center